Related Experiment Video
Updated: Jul 30, 2025

MicroRNA Detection in Prostate Tumors by Quantitative Real-time PCR qPCR
Published on: May 16, 2012
BAZ2A-RNA mediated association with TOP2A and KDM1A represses genes implicated in prostate cancer
Marcin Roganowicz1,2, Dominik Bär1, Cristiana Bersaglieri1
1Department of Molecular Mechanisms of Disease, DMMD, University of Zurich, Zurich, Switzerland.
Abstract:
BAZ2A represses rRNA genes (rDNA) that are transcribed by RNA polymerase I. In prostate cancer (PCa), BAZ2A function goes beyond this role because it represses genes frequently silenced in metastatic disease. However, the mechanisms of this BAZ2A-mediated repression remain elusive. Here, we show that BAZ2A represses genes through its RNA-binding TAM domain using mechanisms differing from rDNA silencing. Although the TAM domain mediates BAZ2A recruitment to rDNA, in PCa, this is not required for BAZ2A association with target genes. Instead, the BAZ2A-TAM domain in association with RNA mediates the interaction with topoisomerase 2A (TOP2A) and histone demethylase KDM1A, whose expression positively correlates with BAZ2A levels in localized and metastatic PCa. TOP2A and KDM1A pharmacological inhibition up-regulate BAZ2A-repressed genes that are regulated by inactive enhancers bound by BAZ2A, whereas rRNA genes are not affected. Our findings showed a novel RNA-based mechanism of gene regulation in PCa. Furthermore, we determined that RNA-mediated interactions between BAZ2A and TOP2A and KDM1A repress genes critical to PCa and may prove to be useful to stratify prostate cancer risk and treatment in patients.
Insights
BAZ2A protein represses genes in prostate cancer via an RNA-binding mechanism involving TOP2A and KDM1A. This novel pathway offers potential for stratifying prostate cancer risk and guiding treatment strategies.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- BAZ2A protein typically represses ribosomal RNA genes (rDNA).
- In prostate cancer (PCa), BAZ2A represses additional genes linked to metastatic disease.
- The precise mechanisms of BAZ2A-mediated repression in PCa are not fully understood.
Purpose of the Study:
- To elucidate the novel mechanisms of BAZ2A-mediated gene repression in prostate cancer.
- To investigate the role of the BAZ2A TAM domain in PCa gene regulation.
- To identify potential therapeutic targets and biomarkers for prostate cancer.
Main Methods:
- Investigated BAZ2A's interaction with target genes and regulatory proteins using its RNA-binding TAM domain.
- Examined the association of BAZ2A with topoisomerase 2A (TOP2A) and KDM1A in PCa cells.
- Utilized pharmacological inhibition of TOP2A and KDM1A to assess their impact on BAZ2A-repressed genes.
Main Results:
- BAZ2A utilizes its TAM domain and associated RNA to interact with TOP2A and KDM1A in PCa.
- TOP2A and KDM1A expression positively correlates with BAZ2A levels in both localized and metastatic PCa.
- Inhibition of TOP2A and KDM1A reactivates BAZ2A-repressed genes regulated by inactive enhancers, distinct from rDNA regulation.
Conclusions:
- Discovered a novel, RNA-based mechanism of gene regulation by BAZ2A in prostate cancer.
- RNA-mediated interactions involving BAZ2A, TOP2A, and KDM1A repress critical PCa genes.
- These findings suggest BAZ2A-TOP2A-KDM1A interactions could be valuable for prostate cancer risk stratification and treatment.
Related Concept Videos
RNA Polymerase II Accessory Proteins
Abnormal Proliferation
Co-activators and Co-repressors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Master Transcription Regulators
MicroRNAs

